(-0.08%) 5 304.25 points
(-0.09%) 40 140 points
(-0.05%) 18 465 points
(-0.07%) $83.11
(-0.62%) $1.752
(0.73%) $2 254.80
(0.74%) $25.10
(0.21%) $923.00
(0.07%) $0.927
(0.35%) $10.88
(0.07%) $0.793
(-0.32%) $92.28
Live Chart Being Loaded With Signals
Hangzhou Tigermed Consulting Co., Ltd. provides contract research organization services in the People's Republic of China and internationally. It operates in Clinical Trial Solutions, and Clinical-related and Laboratory Services segments...
Stats | |
---|---|
Today's Volume | 1.71M |
Average Volume | 2.21M |
Market Cap | 38.02B |
EPS | HKD0.562 ( 2023-09-30 ) |
Last Dividend | HKD0.616 ( 2023-05-25 ) |
Next Dividend | HKD0 ( N/A ) |
P/E | 10.39 |
ATR14 | HKD0.0500 (0.17%) |
Volume Correlation
Hangzhou Tigermed Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Hangzhou Tigermed Correlation - Currency/Commodity
Hangzhou Tigermed Financials
Annual | 2022 |
Revenue: | HKD7.09B |
Gross Profit: | HKD2.81B (39.64 %) |
EPS: | HKD2.32 |
Q3 | 2023 |
Revenue: | HKD1.94B |
Gross Profit: | HKD798.47M (41.17 %) |
EPS: | HKD0.560 |
Q2 | 2023 |
Revenue: | HKD1.91B |
Gross Profit: | HKD765.56M (40.16 %) |
EPS: | HKD0.950 |
Q1 | 2023 |
Revenue: | HKD1.80B |
Gross Profit: | HKD715.52M (39.65 %) |
EPS: | HKD0.660 |
Financial Reports:
No articles found.
Hangzhou Tigermed Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0.616 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | HKD0.362 | 2021-05-25 |
Last Dividend | HKD0.616 | 2023-05-25 |
Next Dividend | HKD0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 3 | -- |
Total Paid Out | HKD1.557 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 2.98 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 6.22 | |
Div. Directional Score | 8.16 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
2886.HK | Ex Dividend Junior | 2023-05-19 | Annually | 0 | 0.00% | |
1522.HK | Ex Dividend Junior | 2023-06-29 | Sporadic | 0 | 0.00% | |
0576.HK | Ex Dividend Knight | 2023-05-08 | Annually | 0 | 0.00% | |
8062.HK | Ex Dividend Knight | 2023-08-17 | Annually | 0 | 0.00% | |
2018.HK | Ex Dividend Knight | 2023-05-29 | Annually | 0 | 0.00% | |
1100.HK | Ex Dividend Knight | 2023-09-14 | Semi-Annually | 0 | 0.00% | |
0179.HK | Ex Dividend Knight | 2023-07-18 | Annually | 0 | 0.00% | |
3692.HK | Ex Dividend Knight | 2023-09-15 | Semi-Annually | 0 | 0.00% | |
1668.HK | No Dividend Player | 2023-09-26 | Annually | 0 | 0.00% | |
0719.HK | Ex Dividend Knight | 2023-07-07 | Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.311 | 1.500 | 3.77 | 5.66 | [0 - 0.5] |
returnOnAssetsTTM | 0.0759 | 1.200 | 7.47 | 8.97 | [0 - 0.3] |
returnOnEquityTTM | 0.112 | 1.500 | 9.87 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0.260 | -1.000 | 7.40 | -7.40 | [0 - 1] |
currentRatioTTM | 2.68 | 0.800 | 1.581 | 1.265 | [1 - 3] |
quickRatioTTM | 2.67 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 1.736 | 1.500 | 1.466 | 2.20 | [0.2 - 2] |
debtRatioTTM | 0.123 | -1.500 | 7.96 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 29.13 | 1.000 | 0.322 | 0.322 | [3 - 30] |
operatingCashFlowPerShareTTM | 1.851 | 2.00 | 9.38 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 1.463 | 2.00 | 9.27 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.175 | -1.500 | 9.30 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.398 | 1.000 | 6.70 | 6.70 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.395 | 1.000 | 4.11 | 4.11 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.438 | 1.000 | 8.68 | 8.68 | [0.2 - 2] |
assetTurnoverTTM | 0.244 | 0.800 | -1.708 | -1.367 | [0.5 - 2] |
Total Score | 10.09 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 10.45 | 1.000 | 9.05 | 0 | [1 - 100] |
returnOnEquityTTM | 0.112 | 2.50 | 9.91 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 1.463 | 2.00 | 9.51 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 2.25 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 1.851 | 2.00 | 9.38 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.260 | 1.500 | 7.40 | -7.40 | [0 - 1] |
pegRatioTTM | 0.120 | 1.500 | -2.54 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.220 | 1.000 | 6.99 | 0 | [0.1 - 0.5] |
Total Score | 6.22 |
Hangzhou Tigermed
Hangzhou Tigermed Consulting Co., Ltd. provides contract research organization services in the People's Republic of China and internationally. It operates in Clinical Trial Solutions, and Clinical-related and Laboratory Services segments. The company offers regulatory submission and approval, medical translation, and good manufacturing practice (GMP) consulting services; and clinical services in the areas of medical science, early clinical and late phase development, medical monitoring, project management, patient recruitment, and quality management system. It also provides biometrics services comprising data management, biostatistics, and statistical programming; and integrated technology services, such as site management, pharmacovigilance, third party audit and training, medical imaging, clinical trial system solution, central laboratory, pre-clinical, and research hospital. Further, the company offers medical device/ in vitro diagnostics (IVD) services comprising medical device testing, regulatory submission, clinical evaluation and trials, GMP certificate, EU MDR and IVDR preparation, and value-added services; and post-marketing study, real world evidence, and vaccine clinical trial services. Hangzhou Tigermed Consulting Co., Ltd. was incorporated in 2004 and is headquartered in Hangzhou, the People's Republic of China.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators